MétaCan
Menu
Back to cohort
Record W4404160023 · doi:10.1002/clt2.70002

GA<sup>2</sup>LEN ANACARE consensus statement: Potential of omalizumab in food allergy management

2024· review· en· W4404160023 on OpenAlexaff
Torsten Zuberbier, Antonella Muraro, Ulugbek Nurmatov, Stefania Arasi, Katarina Stevanovic, Aikaterini Anagnostou, Roberta Bonaguro, R. Sharon Chinthrajah, Gideon Lack, Alessandro Fiocchi, Thuy‐My Le, Paul Turner, Montserrat Álvaro‐Lozano, Elizabeth Angier, Simona Barni, Philippe Bégin, Barbara Ballmer‐Weber, Victória Cardona, Carsten Bindslev‐Jensen, Antonella Cianferoni, Nicolette W. de Jong, Debra de Silva, A. Deschildre, Audrey Dunn Galvin, Motohiro Ebisawa, David M. Fleischer, Jennifer Gerdts, Mattia Giovannini, Josefine Gradman, Susanne Halken, Syed Hasan Arshad, Ekaterina Khaleva, Susanne Lau, Richard Loh, Mika J. Mäkelä, Mary Jane Marchisotto, Laura Morandini, Charlotte G. Mørtz, Caroline Nilsson, Anna Nowak‐Węgrzyn, Márcia Helena Miranda Cardoso Podestá, Lars K. Poulsen, Graham Roberts, Pablo Rodríguez del Río, H. A. Sampson, Ángel Sánchez, Sabine Schnadt, Peter Smith, Hania Szajewska, Natasa Teovska Mitrevska, Alice Toniolo, Carina Venter, Amena Warner, Gary Wong, R.J.K. Wood, Margitta Worm

Bibliographic record

VenueClinical and Translational Allergy · 2024
Typereview
Languageen
FieldMedicine
TopicFood Allergy and Anaphylaxis Research
Canadian institutionsAllerGenCentre Hospitalier de l’Université de MontréalCentre Hospitalier Universitaire Sainte-Justine
FundersMedical Research CouncilNovartis Pharma
KeywordsMedicineOmalizumabFood allergyStatement (logic)AllergyFamily medicineImmunologyImmunoglobulin EAntibody

Abstract

fetched live from OpenAlex

Abstract Immunoglobulin E (IgE)‐mediated food allergies are the most common type of food allergy, often causing rapid symptoms after exposure to allergens posing a serious health risk and a high impact on patient's and caregiver's quality of life. Omalizumab, a humanized anti‐IgE monoclonal antibody, reduces allergic reactions by binding to circulating IgE. Omalizumab has been successfully used in allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic urticaria, and was recently approved for treating IgE‐mediated food allergies by the US Food and Drug Administration (FDA). This GA2LEN ANACARE Consensus Statement presents our position on the use of omalizumab for treating IgE‐mediated food allergies, based on a systematic review and meta‐analysis, experience with use for other conditions, and expert consensus achieved via an eDelphi process. Following publication of the recent OUtMATCH study (stage 1) results and subsequent FDA approval, we propose that there is now sufficient evidence to recommend omalizumab as the only drug currently available that can mechanistically reduce IgE‐mediated food allergic reactions. We acknowledge that the evidence does not reach the highest level of evidence which would be needed for a guideline recommendation.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.021
metaresearch head score (Gemma)0.048
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.021
Threshold uncertainty score0.113

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0210.048
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0040.006
Bibliometrics0.0040.003
Science and technology studies0.0010.001
Scholarly communication0.0040.002
Open science0.0040.002
Research integrity0.0090.005
Insufficient payload (model declined to judge)0.0110.004

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.091
GPT teacher head0.404
Teacher spread0.314 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations16
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueClinical and Translational AllergySame topicFood Allergy and Anaphylaxis ResearchFrench-language works237,207